| ALECTOR INC. |
| USA |
| Gesundheit |
| US0144421072 / A2PCBM |
| 0Z2 (Frankfurt) / ALEC (NASDAQ) |
| FRA:0Z2, ETR:0Z2, 0Z2:GR, NASDAQ:ALEC |
| - |
| https://alector.com/ |
|
Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. Alector Inc. applies its immuno-neurology platform to target the immune dysfunction and protein-related pathology associated with c..
>Volltext.. |
| 179.55 Mio. EUR |
| 57.12 Mio. EUR |
| 12.32 Mio. EUR |
| -97.78 Mio. EUR |
| -104.7 Mio. EUR |
| -0.97 EUR |
| 29.1 Mio. EUR |
| 53.23 Mio. EUR |
| -140.58 Mio. EUR |
| 5.05 |
| -82.38% |
| -5.44% |
| - |
| - |
| - |
| ALECTOR |
| 05.10.26 |
|
||||
|
||||
|
||||
|